Advertisement


John B.A.G. Haanen, MD, PhD, on Melanoma: Phase III Data on Treatment With Tumor-Infiltrating Lymphocytes vs Ipilimumab

ESMO Congress 2022

Advertisement

John B.A.G. Haanen, MD, PhD, of The Netherlands Cancer Institute, discusses recent phase III findings, which show that tumor-infiltrating lymphocytes (TILs) improve progression-free survival compared with ipilimumab by 50% in patients with advanced melanoma after not responding to anti–PD-1 treatment. Around 50% of TIL-treated patients had a response, and 20% had a complete response (Abstract LBA3).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
At the ESMO Congress, I presented the results from the randomized controlled phase three trial comparing infusion with tumor infant lymphocytes to ipilimumab in patients with metastatic melanoma. The trial was designed for patients with cutaneous melanoma having failed at the maximum of one prior treatment. The majority, meaning almost 90% of the patients, had received prior anti PD one treatment when they went on the trial. Patients were randomized to receive either TIL treatment or ipilimumab. In total, 168 patients were randomized one to one, and the primary endpoint of the study was progression free survival by investigative review in the intention to treat population. The results from this trial show a 50% reduction in risk of progression or death, in favor of the TIL treatment compared to ipilimumab. The median progression for survival for the TIL treat patients was 7.2 months compared to a 3.1 months for patients treated with ipilimumab. When we look at the overall response rates, TIL compared much better than ipilimumab. We saw a 49% overall response rate for the TIL treat patients, 20% having complete remission. This compared to 21% for [inaudible 00:01:34] treated patients with 7% complete remission. We did look at the overall survival and there was a trend for better overall survival for patients treated with TIL. However the study was not powered to show this overall survival. The median overall survival for the TIL treated patients was over 25 months compared to over 18 months. Therefore, the ipilimumab treated patients. Side effects occurred in both treatment arms in all patients received that received TIL treatment. They had a grade three or higher adverse events. These adverse events could be attributed to the lymph repeating chemotherapy consisting of cyclophosphamide and [inaudible 00:02:16] or the high dose interleukin-2 that these patient received following TIL infusion. These side effects had completely disappeared by the time the patients were released from the hospital, and there were no long term problems seen in these patients due to side effects. Also, health related quality of life, scores were better in patients treated with TIL compared to ipi, and this was maximum around 18 weeks after treatment. It was still visible at around one year after treatment. So in conclusion, this is the first randomized control trial with a cell therapy in a solid cancer. In this case, treatment with TIL compared to ipilimumab for patient with advanced melanoma. And there was a clear difference in progression for survival and overall response rate in favor of the TIL treated patients and their side effects were manageable, and health related quality of life was better for the TIL treated patients. So we think that TIL therapy could become a new treatment option for patients with metastatic melanoma. In future research, we will look at the infusion products, and also look for correlations between the cells in these infusion products and outcome. And hopefully we will be able to share those results at a later time point.

Related Videos

Gynecologic Cancers

Ana Oaknin, MD, PhD, on Cervical Cancer: New Findings on Cemiplimab in Recurrent or Metastatic Disease

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses an analysis of long-term survival from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Cemiplimab-rwlc is the first immunotherapy to demonstrate an overall survival benefit as a second-line monotherapy for patients with recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy but not immunotherapy. The benefit was sustained in this population (Abstract 519MO).

Hepatobiliary Cancer

Richard S. Finn, MD, on Hepatocellular Carcinoma: Recent Data on Lenvatinib Plus Pembrolizumab

Richard S. Finn, MD, of the Geffen School of Medicine at the University of California, Los Angeles, discusses primary phase III results from the LEAP-002 study of pembrolizumab, an anti–PD-1 therapy, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor, vs lenvatinib monotherapy in patients with advanced hepatocellular carcinoma (Abstract LBA34).

Kidney Cancer
Immunotherapy

Robert J. Motzer, MD, on Renal Cell Carcinoma: New Results With Nivolumab and Ipilimumab

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract LBA4).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).

Kidney Cancer

Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of atezolizumab vs placebo as adjuvant therapy in patients with RCC at increased risk of recurrence after nephrectomy; and CheckMate 914, which compared nivolumab monotherapy or nivolumab combined with ipilimumab vs placebo in patients with localized disease who underwent radical or partial nephrectomy and who are at high risk of relapse. (Abstract LBA4 & LBA66).

Advertisement

Advertisement




Advertisement